Cargando…

Bronchoscopic Endobronchial Valve Therapy for Persistent Air Leaks in COVID-19 Patients Requiring Veno-Venous Extracorporeal Membrane Oxygenation

COVID-19 acute respiratory distress syndrome (ARDS) can be associated with extensive lung damage, pneumothorax, pneumomediastinum and, in severe cases, persistent air leaks (PALs) via bronchopleural fistulae (BPF). PALs can impede weaning from invasive ventilation or extracorporeal membrane oxygenat...

Descripción completa

Detalles Bibliográficos
Autores principales: Ficial, Barbara, Whebell, Stephen, Taylor, Daniel, Fernández-Garda, Rita, Okiror, Lawrence, Meadows, Christopher I. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962378/
https://www.ncbi.nlm.nih.gov/pubmed/36835885
http://dx.doi.org/10.3390/jcm12041348
_version_ 1784895989533900800
author Ficial, Barbara
Whebell, Stephen
Taylor, Daniel
Fernández-Garda, Rita
Okiror, Lawrence
Meadows, Christopher I. S.
author_facet Ficial, Barbara
Whebell, Stephen
Taylor, Daniel
Fernández-Garda, Rita
Okiror, Lawrence
Meadows, Christopher I. S.
author_sort Ficial, Barbara
collection PubMed
description COVID-19 acute respiratory distress syndrome (ARDS) can be associated with extensive lung damage, pneumothorax, pneumomediastinum and, in severe cases, persistent air leaks (PALs) via bronchopleural fistulae (BPF). PALs can impede weaning from invasive ventilation or extracorporeal membrane oxygenation (ECMO). We present a series of patients requiring veno-venous ECMO for COVID-19 ARDS who underwent endobronchial valve (EBV) management of PAL. This is a single-centre retrospective observational study. Data were collated from electronic health records. Patients treated with EBV met the following criteria: ECMO for COVID-19 ARDS; the presence of BPF causing PAL; air leak refractory to conventional management preventing ECMO and ventilator weaning. Between March 2020 and March 2022, 10 out of 152 patients requiring ECMO for COVID-19 developed refractory PALs, which were successfully treated with bronchoscopic EBV placement. The mean age was 38.3 years, 60% were male, and half had no prior co-morbidities. The average duration of air leaks prior to EBV deployment was 18 days. EBV placement resulted in the immediate cessation of air leaks in all patients with no peri-procedural complications. Weaning of ECMO, successful ventilator recruitment and removal of pleural drains were subsequently possible. A total of 80% of patients survived to hospital discharge and follow-up. Two patients died from multi-organ failure unrelated to EBV use. This case series presents the feasibility of EBV placement in severe parenchymal lung disease with PAL in patients requiring ECMO for COVID-19 ARDS and its potential to expedite weaning from both ECMO and mechanical ventilation, recovery from respiratory failure and ICU/hospital discharge.
format Online
Article
Text
id pubmed-9962378
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99623782023-02-26 Bronchoscopic Endobronchial Valve Therapy for Persistent Air Leaks in COVID-19 Patients Requiring Veno-Venous Extracorporeal Membrane Oxygenation Ficial, Barbara Whebell, Stephen Taylor, Daniel Fernández-Garda, Rita Okiror, Lawrence Meadows, Christopher I. S. J Clin Med Article COVID-19 acute respiratory distress syndrome (ARDS) can be associated with extensive lung damage, pneumothorax, pneumomediastinum and, in severe cases, persistent air leaks (PALs) via bronchopleural fistulae (BPF). PALs can impede weaning from invasive ventilation or extracorporeal membrane oxygenation (ECMO). We present a series of patients requiring veno-venous ECMO for COVID-19 ARDS who underwent endobronchial valve (EBV) management of PAL. This is a single-centre retrospective observational study. Data were collated from electronic health records. Patients treated with EBV met the following criteria: ECMO for COVID-19 ARDS; the presence of BPF causing PAL; air leak refractory to conventional management preventing ECMO and ventilator weaning. Between March 2020 and March 2022, 10 out of 152 patients requiring ECMO for COVID-19 developed refractory PALs, which were successfully treated with bronchoscopic EBV placement. The mean age was 38.3 years, 60% were male, and half had no prior co-morbidities. The average duration of air leaks prior to EBV deployment was 18 days. EBV placement resulted in the immediate cessation of air leaks in all patients with no peri-procedural complications. Weaning of ECMO, successful ventilator recruitment and removal of pleural drains were subsequently possible. A total of 80% of patients survived to hospital discharge and follow-up. Two patients died from multi-organ failure unrelated to EBV use. This case series presents the feasibility of EBV placement in severe parenchymal lung disease with PAL in patients requiring ECMO for COVID-19 ARDS and its potential to expedite weaning from both ECMO and mechanical ventilation, recovery from respiratory failure and ICU/hospital discharge. MDPI 2023-02-08 /pmc/articles/PMC9962378/ /pubmed/36835885 http://dx.doi.org/10.3390/jcm12041348 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ficial, Barbara
Whebell, Stephen
Taylor, Daniel
Fernández-Garda, Rita
Okiror, Lawrence
Meadows, Christopher I. S.
Bronchoscopic Endobronchial Valve Therapy for Persistent Air Leaks in COVID-19 Patients Requiring Veno-Venous Extracorporeal Membrane Oxygenation
title Bronchoscopic Endobronchial Valve Therapy for Persistent Air Leaks in COVID-19 Patients Requiring Veno-Venous Extracorporeal Membrane Oxygenation
title_full Bronchoscopic Endobronchial Valve Therapy for Persistent Air Leaks in COVID-19 Patients Requiring Veno-Venous Extracorporeal Membrane Oxygenation
title_fullStr Bronchoscopic Endobronchial Valve Therapy for Persistent Air Leaks in COVID-19 Patients Requiring Veno-Venous Extracorporeal Membrane Oxygenation
title_full_unstemmed Bronchoscopic Endobronchial Valve Therapy for Persistent Air Leaks in COVID-19 Patients Requiring Veno-Venous Extracorporeal Membrane Oxygenation
title_short Bronchoscopic Endobronchial Valve Therapy for Persistent Air Leaks in COVID-19 Patients Requiring Veno-Venous Extracorporeal Membrane Oxygenation
title_sort bronchoscopic endobronchial valve therapy for persistent air leaks in covid-19 patients requiring veno-venous extracorporeal membrane oxygenation
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9962378/
https://www.ncbi.nlm.nih.gov/pubmed/36835885
http://dx.doi.org/10.3390/jcm12041348
work_keys_str_mv AT ficialbarbara bronchoscopicendobronchialvalvetherapyforpersistentairleaksincovid19patientsrequiringvenovenousextracorporealmembraneoxygenation
AT whebellstephen bronchoscopicendobronchialvalvetherapyforpersistentairleaksincovid19patientsrequiringvenovenousextracorporealmembraneoxygenation
AT taylordaniel bronchoscopicendobronchialvalvetherapyforpersistentairleaksincovid19patientsrequiringvenovenousextracorporealmembraneoxygenation
AT fernandezgardarita bronchoscopicendobronchialvalvetherapyforpersistentairleaksincovid19patientsrequiringvenovenousextracorporealmembraneoxygenation
AT okirorlawrence bronchoscopicendobronchialvalvetherapyforpersistentairleaksincovid19patientsrequiringvenovenousextracorporealmembraneoxygenation
AT meadowschristopheris bronchoscopicendobronchialvalvetherapyforpersistentairleaksincovid19patientsrequiringvenovenousextracorporealmembraneoxygenation